Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $215.7 million.

  • Apellis Pharmaceuticals' Income from Continuing Operations rose 475.46% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Income from Continuing Operations stood at $215.7 million, which was up 611.35% from -$42.2 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Income from Continuing Operations high stood at $215.7 million for Q3 2025, and its period low was -$219.2 million during Q2 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Income from Continuing Operations value was -$66.5 million (recorded in 2024), while the average stood at -$58.7 million.
  • In the last 5 years, Apellis Pharmaceuticals' Income from Continuing Operations slumped by 222.56% in 2021 and then skyrocketed by 475.46% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Income from Continuing Operations stood at -$147.9 million in 2021, then fell by 12.21% to -$166.0 million in 2022, then skyrocketed by 46.64% to -$88.6 million in 2023, then soared by 58.99% to -$36.3 million in 2024, then skyrocketed by 475.46% to $215.7 million in 2025.
  • Its last three reported values are $215.7 million in Q3 2025, -$42.2 million for Q2 2025, and -$92.2 million during Q1 2025.